Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Lin Gu, MS, Guan Xing, PhD, Nishan Rajakumaraswamy, MD, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD

Blood (2019) 134 (Supplement_1): 5468.

https://doi.org/10.1182/blood-2019-124541

Published: 2019

Journal Articles

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

David Andorsky, MD, Rebecca J Chan, MD PhD, Jamyia Clark, MPH, Bianca Ruzicka, PhD, Nicholas James Robert, MD, Farrukh T. Awan, MD

Blood (2019) 134 (Supplement_1): 2810.

https://doi.org/10.1182/blood-2019-124013

Published: 2019

Journal Articles

Combined Pharmacological Inhibition of Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3-Kinase (PI3K) p110δ Rescues Monocytosis, Thrombocytopenia, and Splenomegaly in a Genetic Mouse Model for JMML

Roshni Patel, BS, Baskar Ramdas, PhD, Lisa Deng, PhD, Victoria Jideonwo-Auman, PhD, Rebecca J Chan, MD PhD, Reuben Kapur, PhD

Blood (2018) 132 (Supplement 1): 2623.

https://doi.org/10.1182/blood-2018-99-118802

Published: 2018

Journal Articles

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Jennifer R. Brown, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Susan M. O'Brien, MD

Blood (2018) 132 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2018-99-110853

Published: 2018

Journal Articles

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Shuo Ma, MD PhD, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Carrie Ellen Brubaker, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 3149.

https://doi.org/10.1182/blood-2018-99-110655

Published: 2018

Journal Articles

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Farrukh T. Awan, MD MS, Rebecca J Chan, MD PhD, Wei Ye, PhD, Guan Xing, PhD, Caroline Roudet, PharmD, MBA, Bianca Ruzicka, PhD, Martin Dreyling, MD PhD, Pier Luigi Zinzani, MD, Ajay K. Gopal, MD

Blood (2018) 132 (Supplement 1): 5322.

https://doi.org/10.1182/blood-2018-99-110477

Published: 2018

Journal Articles

Pharmacologic Inhibition of PI3Kδ Prolongs Survival of Mutant Shp2 E76K -Expressing Mice

Lisa Deng, Elizabeth L Virts, PhD, Rebecca J Chan, MD PhD

Blood (2017) 130 (Supplement 1): 1240.

https://doi.org/10.1182/blood.V130.Suppl_1.1240.1240

Published: 2017

Journal Articles

PTPN11 D61Y/+ ; Vavcre+ Animals Commonly Succumb to Leukemia Relapse Despite Robust Engraftment of Transplanted Wild-Type Hematopoietic Stem and Progenitor Cells

Stefan P. Tarnawsky, BS, Mervin C. Yoder, MD, Rebecca J. Chan, MD, PhD

Blood (2016) 128 (22): 496.

https://doi.org/10.1182/blood.V128.22.496.496

Published: 2016

Journal Articles

Macrophage NADPH Oxidase Activation and ROS Production Is Positively Regulated By Shp2 Phosphatase Function

XingJun Li, MD PhD, Charles Goodwin, BS, Zhenyun Yang, Sarah C Nabinger, PhD, Briana Richine, Gordon Chan, Helmut Hanenberg, Hiroaki Ohnishi, MD, Takashi Matozaki, MD PhD, Jamel El Benna, Gen-Sheng Feng, PhD, Benjamin Neel, MD PhD, Rebecca J. Chan, MD PhD

Blood (2014) 124 (21): 1397.

https://doi.org/10.1182/blood.V124.21.1397.1397

Published: 2014

Journal Articles

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

Lili Chen, PhD, Wei Chen, PhD, Maria Mysliwski, Justin Serio, James Ropa, Fardokht Abulwerdi, Rebecca J. Chan, MD PhD, Jay P. Patel, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Ari M Melnick, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Zaneta Nikolovska-Coleska, PhD, Andrew G. Muntean, PhD

Blood (2014) 124 (21): 3565.

https://doi.org/10.1182/blood.V124.21.3565.3565

Published: 2014

Journal Articles

HSC-Independent Yolk Sac Progenitors Bear Hallmarks of JMML in a PTPN11 D61Y Mouse Model

Stefan Pasichnyk Tarnawsky, B.Sc., Momoko Yoshimoto, MD PhD, Gordon Chan, PhD, Benjamin Neel, MD PhD, Rebecca J. Chan, MD PhD, Mervin C. Yoder, MD

Blood (2014) 124 (21): 3236.

https://doi.org/10.1182/blood.V124.21.3236.3236

Published: 2014

Journal Articles

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML

Charles B Goodwin, Xing Jun Li, Raghuveer S. Mali, Gordon Chan, Michelle Kang, Ziyue Liu, Bart Vanhaesebroeck, Benjamin G. Neel, Mignon L. Loh, Brian J. Lannutti, Reuben Kapur, Rebecca J. Chan

Blood (2014) 123 (18): 2838–2842.

https://doi.org/10.1182/blood-2013-10-535104

Published: 2014

Journal Articles

Phosphatidylinositol-3-Kinase p110d Uniquely Promotes Gain-Of-Function PTPN11 -Induced GM-CSF Hypersensitivity In a Model Of Juvenile Myelomonocytic Leukemia

Charles B Goodwin, Raghuveer Mali, Ph.D., Gordon Chan, Benjamin Neel, Brian Lannutti, Reuben Kapur, PhD, Rebecca J. Chan, MD, PhD

Blood (2013) 122 (21): 3678.

https://doi.org/10.1182/blood.V122.21.3678.3678

Published: 2013

Journal Articles

JMML patient-derived iPSCs induce new hypotheses

Rebecca J. Chan, Mervin C. Yoder

Blood (2013) 121 (24): 4815–4817.

https://doi.org/10.1182/blood-2013-05-500090

Published: 2013

Journal Articles

Unraveling a Novel Mechanism of Stat5 Regulation by FAK and Rac1 in Flt3ITD Induced Leukemogenesis

Anindya Chatterjee, MS, PhD, Joydeep Ghosh, Baskar Ramdas, Ph.D., Sasidhar Vemula, PhD, Holly Martin, Raghuveer Mali, Ph.D., Sarah C Nabinger, PhD, Charles B Goodwin, H. Scott Boswell, MD, Rebecca J. Chan, MD, PhD, Reuben Kapur, PhD

Blood (2012) 120 (21): 858.

https://doi.org/10.1182/blood.V120.21.858.858

Published: 2012

Journal Articles

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells.

Sarah C Nabinger, PhD, Xing Jun Li, MD, PhD, Baskar Ramdas, Ph.D., Yantao He, PhD, Xian Zhang, Ph.D., Briana Richine, Joshua Bowling, Seiji Fukuda, MD, PhD, Shreevrat Goenka, Ph.D., Ziyue Liu, Ph.D., Gen-Sheng Feng, PhD, Menggang Yu, Ph.D., George Sandusky, MD, H. Scott Boswell, MD, Zhong-Yin Zhang, PhD, Reuben Kapur, PhD, Rebecca J. Chan, MD, PhD

Blood (2012) 120 (21): 2420.

https://doi.org/10.1182/blood.V120.21.2420.2420

Published: 2012

Journal Articles

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT

Blood (2012) 120 (13): 2669–2678.

https://doi.org/10.1182/blood-2011-08-375873

Published: 2012

Includes: Supplemental data

Journal Articles

KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML

Peilin Ma, MD, PhD, Raghuveer Mali, Ph.D., Li-Fan Zeng, PhD, Holly Martin, Baskar Ramdas, Ph.D., Yantao He, PhD, Emily Sims, Joydeep Ghosh, Ph.D, Sarah C Nabinger, Shuo Li, Veerendra Munugalavadla, PhD, Anindya Chatterjee, PhD, George Sandusky, MD, Andrew Craig, PhD, Kevin D. Bunting, PhD, Gen-Sheng Feng, Rebecca J. Chan, MD, PhD, Zhong-Yin Zhang, PhD, Reuben Kapur, PhD

Blood (2011) 118 (21): 868.

https://doi.org/10.1182/blood.V118.21.868.868

Published: 2011

Journal Articles

The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor

Peilin Ma, Raghuveer Singh Mali, Veerendra Munugalavadla, Subha Krishnan, Baskar Ramdas, Emily Sims, Holly Martin, Joydeep Ghosh, Shuo Li, Rebecca J. Chan, Gerald Krystal, Andrew W. Craig, Clifford Takemoto, Reuben Kapur

Blood (2011) 118 (13): 3459–3469.

https://doi.org/10.1182/blood-2011-04-351809

Published: 2011

Journal Articles

Genetic Disruption of the PI3K Regulatory Subunit, p85α Partially Normalizes Gain-of-Function PTPN11-Induced Hypersensitivity to GM-CSF in Hematopoietic Progenitors.

Charles B Goodwin, Zhenyun Yang, Sasidhar Vemula, Fuqin Yin, Reuben Kapur, PhD, Rebecca J. Chan, MD, PhD

Blood (2009) 114 (22): 3968.

https://doi.org/10.1182/blood.V114.22.3968.3968

Published: 2009

NARROW

Impact of Idelalisib Treatment Interruption with or without Dose Reduction on Outcomes in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Treatment Patterns and Outcomes of Patients with Relapsed or Refractory Follicular Lymphoma Treated with Idelalisib in a Community Oncology Setting

Combined Pharmacological Inhibition of Bruton's Tyrosine Kinase (BTK) and Phosphoinositide 3-Kinase (PI3K) p110δ Rescues Monocytosis, Thrombocytopenia, and Splenomegaly in a Genetic Mouse Model for JMML

Idelalisib Plus Anti-CD20 Used Second Line Shows Improved PFS and Comparable Safety Compared to Later Line Therapy of Relapsed CLL

Survival Outcomes Following Idelalisib Interruption in the Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia

Patient Co-Morbidity Profile Should Drive PI3K Inhibitor Selection for Relapsed Follicular Lymphoma

Pharmacologic Inhibition of PI3Kδ Prolongs Survival of Mutant Shp2 E76K -Expressing Mice

PTPN11 D61Y/+ ; Vavcre+ Animals Commonly Succumb to Leukemia Relapse Despite Robust Engraftment of Transplanted Wild-Type Hematopoietic Stem and Progenitor Cells

Macrophage NADPH Oxidase Activation and ROS Production Is Positively Regulated By Shp2 Phosphatase Function

Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression

HSC-Independent Yolk Sac Progenitors Bear Hallmarks of JMML in a PTPN11 D61Y Mouse Model

PI3K p110δ uniquely promotes gain-of-function Shp2-induced GM-CSF hypersensitivity in a model of JMML

Phosphatidylinositol-3-Kinase p110d Uniquely Promotes Gain-Of-Function PTPN11 -Induced GM-CSF Hypersensitivity In a Model Of Juvenile Myelomonocytic Leukemia

JMML patient-derived iPSCs induce new hypotheses

Unraveling a Novel Mechanism of Stat5 Regulation by FAK and Rac1 in Flt3ITD Induced Leukemogenesis

The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells.

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT

KIT Induced Myeloproliferative Disease Is Dependent on PI3Kinase and SHP2 Phosphatase: Identification of SHP2 As a Druggable Target for Treating MPD and AML

The PI3K pathway drives the maturation of mast cells via microphthalmia transcription factor

Genetic Disruption of the PI3K Regulatory Subunit, p85α Partially Normalizes Gain-of-Function PTPN11-Induced Hypersensitivity to GM-CSF in Hematopoietic Progenitors.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only